
    
      This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment
      with SOF/VEL FDC for 8 weeks in patients with acute HCV infection as measured by the
      proportion of subjects with sustained viral response (undetectable HCV RNA) 12 weeks after
      stop of therapy.
    
  